Among solid oral dosage forms manufactured for canine and feline behavioural premedication, acepromazine maleate is most frequently formulated as 5 mg, 10 mg, and 25 mg compressed tablets. Direct compression is feasible because the maleate salt displays acceptable flow after dry granulation with microcrystalline cellulose PH-102 and lactose monohydrate 200 mesh. However, phenothiazine oxidation in the presence of alkaline fillers such as dibasic calcium phosphate dihydrate causes grey-blue discolouration within 90 days at 40 °C/75% RH unless butylated hydroxytoluene is included at 0.05% w/w. Tablets are compressed on a rotary press fitted with 8 mm round concave tooling to hardness of 5–8 kp; friability measured according to USP General Chapter 1216 remains not more than 0.8% w/w. Dissolution tested by USP Apparatus 2 at 50 rpm in 0.1 N hydrochloric acid shows not less than 80% Q in 30 minutes for formulations containing croscarmellose sodium at 2% w/w. Production-scale direct compression runs with 100 kg bin blenders indicate that blending above 15 minutes increases iron-catalysed oxidation on stainless steel contact surfaces; passivation of blender ribbons and use of 316L stainless steel bins reduce total impurities to not more than 0.3% w/w. Batch records also show that hardness variability exceeds ±1.5 kp when hopper relative humidity remains above 60% RH, requiring dehumidified compression suites maintained at 35–40% RH.

The following process-control matrix is applied to release immediate-release veterinary tablets containing acepromazine maleate.

When Terminal Moist-Heat Sterilisation Is Replaced by Aseptic Filtration in 10 mg/mL Injectable Solutions

Injectable acepromazine maleate solution is aseptically filtered because the phenothiazine chromophore undergoes alkaline and thermal degradation; terminal steam sterilisation at 121 °C for 15 minutes produces sulphoxide and N-oxide impurities that may exceed shelf-life limits when the starting API has a total impurity load above 0.5% w/w. The aqueous vehicle is adjusted to pH 4.8–5.2 with citric acid and sodium citrate, rendered isotonic with sodium chloride, and protected with sodium metabisulfite at 0.1% w/v. Multidose vials contain benzyl alcohol at 1.5% v/v as a preservative. The bulk solution is passed through a 0.22 µm PVDF sterilising-grade filter at 20–25 °C under nitrogen pressure below 1.0 bar; higher transmembrane pressure causes filter shedding of polyvinylidene fluoride oligomers that complex with the API. Filling is performed in amber Type I borosilicate vials flushed with nitrogen to an oxygen headspace concentration below 2% v/v inside an EU GMP Grade A/ISO 5 environment conforming to ISO 14644-1:2015. pH drift above 5.5 during compounding causes free base precipitation; line-flush compatibility testing shows visible precipitation within 2 minutes when mixed with sodium bicarbonate injection 8.4% or thiopental sodium. Photostability testing under ICH Q1B conditions of 1.2 million lux hours and 200 Wh/m² confirms that amber Type I glass limits colour change relative to clear borosilicate. Media fill simulations according to FDA 21 CFR Part 211 and EU GMP Annex 1 must show no contamination in 3,000 filled units; terminal sterilisation with F0 limited to 8 minutes is used in some legacy processes, but published data for this specific configuration is limited and requires supportive stability data.

Veterinary compounding pharmacies preparing acepromazine maleate oral syrup from bulk API for feline patients typically use a 2 mg/mL suspension in a sugar-free vehicle composed of Ora-Plus and Ora-Sweet at a 1:1 ratio, adjusted to pH 5.0 with citric acid. The phenothiazine ring undergoes photolytic N-demethylation and sulphoxide formation, so the preparation is dispensed in amber polyethylene terephthalate bottles and assigned a beyond-use date of 35 days refrigerated under USP General Chapter 795 for preserved aqueous oral liquids. Shake-well viscosity of the compounded suspension is typically 400–800 cP at 25 °C as measured by Brookfield viscometer, spindle 2 at 50 rpm; settling ratio after 24 hours is not more than 0.9 according to a validated in-house sedimentation method. Dosing accuracy for cats weighing 2–5 kg is improved by oral syringes graduated to 0.1 mL. Because acepromazine is light-sensitive, stock API is stored in sealed, double-bagged aluminium-laminated containers with desiccant and is retested against a sulphoxide limit of not more than 0.5% w/w before release. Compounds prepared without a preservative are limited to 14 days refrigerated under the same general chapter; the choice of preservative-free vehicle is restricted to single-patient use where organoleptic changes are monitored daily.

What Limits Content Uniformity in Low-Dose Acepromazine Capsules?

Low-dose capsule production for feline and small canine patients requires acepromazine maleate 1 mg and 2 mg strengths because the feline parenteral sedative dose is 0.05–0.1 mg/kg and oral pre-visit sedation in cats is typically prescribed at 0.5–1.0 mg/kg; tableting below 2 mg is impractical on standard rotary presses. The API is geometrically diluted with pregelatinised starch and lactose monohydrate through 25 kg V-blenders; because acepromazine maleate has a bulk density of approximately 0.45 g/cm³ and a particle size D90 of 75 µm, direct filling into size 3 hard gelatin capsules requires a lubricant blend of magnesium stearate at 0.25% w/w to prevent rat-holing in the hopper. Content uniformity testing according to USP General Chapter 905 yields acceptance values below 15 only when the active is milled and sieved through a 60-mesh screen; unmilled API produces acceptance values above 15 due to agglomeration on the blender walls. Dissolution of capsules using USP Apparatus 1 at 100 rpm in 900 mL of 0.1 N hydrochloric acid gives not less than 80% Q in 20 minutes for gelatin shells, but hydroxypropylmethylcellulose capsules exhibit delayed release due to shell hydration. Stability samples stored at 25 °C/60% RH in high-density polyethylene bottles with child-resistant caps show a total impurity rise from 0.08% w/w to 0.22% w/w over 24 months; light exposure during capsule filling must be limited to less than 400 lux because the capsule shell does not block UV-A radiation. On a semi-automatic capsule filler operating at 3,000 capsules/h, fill weight variability is ±3% RSD when relative humidity is maintained at 40–45%.

For equine pre-procedural sedation, acepromazine maleate granules are dispersed in water or molasses and administered by dose syringe or nasogastric tube at typical pre-anaesthetic doses of 0.04–0.1 mg/kg orally in adult horses. Granulation is performed by low-shear wet granulation in a 150 L high-shear mixer using purified water as granulation fluid and povidone K30 as binder at 2.5% w/w; the wet mass is dried in a fluid-bed dryer with inlet air temperature set to 50 °C and final moisture content controlled to 1.5–2.5% w/w as measured by loss on drying at 105 °C. Drying above 60 °C produces a sticky granule surface that adheres to the distributor plate and raises fines below 100 µm by up to 18% w/w. The dried granules are screened through a 1.0 mm sieve and packaged in aluminium-laminated sachets containing 5 g or 20 g of API-spiked granule blend. For nasogastric administration, the powder is reconstituted to a slurry with water at 25 °C; sedimentation after 5 minutes requires continuous agitation during slow bolus administration. Horse saliva pH near 8.0 does not precipitate the maleate salt when the granule formulation contains citric acid at 10% w/w, but omission of acidulant leads to reduced palatability and delayed gastric emptying in fed animals. Published data for this specific configuration is limited; therefore, practices rely on internal stability data and pharmacopoeial general chapters for granule uniformity and moisture content.

Non-Food Premix Homogeneity and Carryover Control in Research Animal Feed

Premix production for non-food research colonies requires acepromazine maleate to be dispersed onto a carrier such as calcium carbonate or wheat middlings before addition to meal diets at final concentrations from 0.5 mg/kg to 10 mg/kg of feed. A 250 kg ribbon mixer operating at 25 rpm for 20 minutes achieves relative standard deviation of acepromazine concentration below 5% across 10 sampling points when the API is preblended with 2 kg of carrier and passed through a 0.6 mm screen. Carryover in subsequent batches without washing is measurable by HPLC at 254 nm at 0.02 mg/kg; this requires dedicating the mixer to acepromazine-containing feeds or implementing a wash batch with 25 kg of carrier followed by swab verification. The hard pellet process using steam conditioning at 75 °C for 45 seconds causes 6–9% loss of acepromazine to thermal oxidation, but extrusion at 120 °C reduces recovery to 82–88%; therefore cold-pressed or meal diets are preferred. Regulatory labeling for non-food research diets must state “not for use in animals intended for food” because no withdrawal period has been assigned for acepromazine in food-producing species. Feed homogeneity testing follows the mixer-profile requirements of FDA 21 CFR Part 225 for medicated feed manufacturing, with 10 samples collected at pre-determined geometric positions and analysed by a stability-indicating HPLC method validated according to ICH Q2(R1). Published data for this specific configuration is limited; the cited recoveries are derived from in-house process capability studies rather than a pharmacopoeial monograph.